OncoLink Cancer Treatment and Resources
OncoLink Cancer Treatment and Resources
Link to OncoLink

IMRT for Head and Neck Cancer: Updated Clinical Results

S. Jack Wei, MD
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 22 de octubre del 2003

Moderator: Theodore L. Phillips, MD., University of California, San Francisco

Nancy Lee, MD, Memorial Sloan-Kettering Cancer Center, New York

  • Approximately 150 papers have reported on the outcomes of H&N cancer patients treated with IMRT.
  • The primary endpoints for these trials usually are rates of xerostomia and local control.
  • It is important to keep in mind that GTV delineation is a multidisciplinary approach requiring the input of the radiation oncologist, neuroradiologist, and the H&N surgeon.
  • CTV delineation requires knowledge of H&N anatomy and patterns of spread.
  • In terms of xerostomia, mean parotid doses of <26 Gy has resulted in objective and subjective salivary function preservation and improved quality of life.
  • IMRT has resulted in 82% improvement in xerostomia at 12 months compared to 40% improvement with 3DCRT.
  • In terms of local control (LC) in nasopharyngeal cancer, comparison to historical controls have shown the following:
  • For T1-2 lesions, IMRT 92-100% vs. 3DCRT 64-95%
  • For T3-4 lesions, IMRT 92-94% vs. 44-68%
  • For oropharyngeal CA, comparison to historical controls for LC have shown:
  • For T1-2 lesions, IMRT 92% vs. 3DCRT 70-90%
  • For T3-4 lesions, IMRT 87-94% vs. 3DCRT 30-70%
  • Similar high rates of LC are seen for other H&N sites.
  • In conclusion, IMRT has been shown to decrease xerostomia rates and possibly increase local control compared to historical controls, particularly in patients with more advanced disease.
  • These patients may experience higher acute toxicity and likely have an increased risk of second malignancy (from 1% to 1.75%) due to the higher integral dose delivered with IMRT.
  • Although randomized trials would be beneficial, it would be difficult to enroll patients into these studies given the existing, non-randomized data.
  • Two ongoing European trials are currently examining these questions, and the results are eagerly anticipated.

OncoLink I wish u knew...

Common misconceptions and myths about pain medication and pain control. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy

Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS